Azamian Bobak R. 4

4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 18, 2025

Form 4

Period: 2025-03-15

DirectorPresident/CEO and Board Chair

Transactions

Exercise/Conversion
Restricted Stock Units
2025-03-15−11,299→ 11,300 total
→ Common Stock (11,299 underlying)
Exercise/Conversion
Common Stock
2025-03-15+51,395→ 77,851 total
Exercise/Conversion
Restricted Stock Units
2025-03-15−23,121→ 69,364 total
→ Common Stock (23,121 underlying)
Exercise/Conversion
Restricted Stock Units
2025-03-15−16,975→ 33,950 total
→ Common Stock (16,975 underlying)

Holdings

Footnotes (6)

[F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
[F2]The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
[F3]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
[F4]RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025 and 2026, subject to the Reporting Person's continuous service.
[F5]RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
[F6]RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

Documents

1 file